Investigational drug may reduce involuntary movements

April 12, 2011

Results of the first randomized, placebo-controlled long-term clinical trial show the investigational drug safinamide may reduce dyskinesia or involuntary movements in mid-to-late stage Parkinson's disease. The findings will be presented as late-breaking research at the 63rd Annual Meeting of the American Academy of Neurology, April 9, 2011, in Honolulu.

"Our findings over a two-year treatment period suggest that taking safinamide in addition to levodopa and other dopaminergic treatments could help patients who continue to experience tremors and involuntary movement problems," said study author Ravi Anand, MD, a consultant with Newron Pharmaceuticals in Bresso, Italy. "These results are an important step forward in understanding how safinamide impacts patients with severe . Symptoms of Parkinson`s disease, motor fluctuations and dyskinesia can greatly affect a person's daily living and quality of life."

For the two-year study, 669 patients with mid-to-late stage Parkinson's disease who were already taking levodopa and other dopaminergic treatments were given 50 or 100 milligrams of safinamide per day or a placebo pill. Scientists tested participant's movement ability using the United Parkinson's disease rating scale that measures activities such as tremor, speech, behavior, mood and daily activities including swallowing, dressing and walking. A specific tool measuring severity of dyskinesia (DRS) was used in addition as primary efficacy endpoint.

At the start of the study, patients who took the 50 milligram dose of safinamide had an average score of 3.9 compared to a score of 3.4 for those taking a placebo pill. Patients who took the 100 milligram dose had an average score of 3.7.

After two years, researchers discovered in a post-hoc analysis that safinamide at 100 milligrams a day on top of taking reduced dyskinesia, or movement problems, by 24 percent in the one-third of participants who had scored a four or higher on the dyskinesia rating scale at the beginning of the study compared to those taking a placebo. There were no significant differences for people who took the 50 milligram dose.

There were no significant differences in the primary efficacy measure (movement control, i.e., dyskinesia) scores in the overall population. Side effects were comparable among the three treatment groups.

Related Stories

Recommended for you

Small but distinct differences among species mark evolution of human brain

November 23, 2017
The most dramatic divergence between humans and other primates can be found in the brain, the primary organ that gives our species its identity.

Team constructs whole-brain map of electrical connections key to forming memories

November 22, 2017
A team of neuroscientists at the University of Pennsylvania has constructed the first whole-brain map of electrical connectivity in the brain based on data from nearly 300 neurosurgical patients with electrodes implanted ...

To forget or to remember? Memory depends on subtle brain signals, scientists find

November 22, 2017
The fragrance of hot pumpkin pie can bring back pleasant memories of holidays past, while the scent of an antiseptic hospital room may cause a shudder. The power of odors to activate memories both pleasing and aversive exists ...

What if consciousness is not what drives the human mind?

November 22, 2017
Everyone knows what it feels like to have consciousness: it's that self-evident sense of personal awareness, which gives us a feeling of ownership and control over the thoughts, emotions and experiences that we have every ...

Pitch imperfect? How the brain decodes pitch may improve cochlear implants

November 22, 2017
Picture yourself with a friend in a crowded restaurant. The din of other diners, the clattering of dishes, the muffled notes of background music, the voice of your friend, not to mention your own – all compete for your ...

New research suggests high-intensity exercise boosts memory

November 22, 2017
The health advantages of high-intensity exercise are widely known but new research from McMaster University points to another major benefit: better memory.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.